The Latest Breakthrough in Breast Cancer Treatment

H&O Can you go into the details of elacestrant’s US Food and Drug Administration (FDA) approval? SMT Elacestrant (Orserdu, Stemline) is an oral selective estrogen receptor […]

Highlights in Breast Cancer

Addition of Ribociclib to Endocrine Therapy Improves Outcomes in Early-Stage, HR+/HER2– Breast Cancer The addition of ribociclib (Kisqali, Novartis) to endocrine therapy improves invasive disease–free survival […]

Highlights in Metastatic Breast Cancer from the 2022 San Antonio Breast Cancer Symposium

A Review of Selected Presentations from SABCS 2022 • San Antonio, TX • December 6-10, 2022 EMERALD Phase 3 Trial of Elacestrant Versus Standard of Care […]

Progress in the Treatment of Breast Cancer: Increased Survival, Improved Patient Experience, and Advances in Drug Formulation

A Review of Selected Presentations From the 2022 San Antonio Breast Cancer Symposium® • December 6-11, 2022 • San Antonio, Texas Sacituzumab Govitecan vs Treatment of […]

Systemic Management of Brain Metastases in HER2+ Breast Cancer in 2022

Abstract: Up to half of all patients with metastatic human epidermal growth factor receptor 2–positive (HER2+) breast cancer will eventually acquire brain metastases (BrMs), which are […]

Highlights in Metastatic Breast Cancer From the 2021 San Antonio Breast Cancer Symposium

A Review of Selected Presentations From the 2021 SABCS December 7-10, 2021 • San Antonio, Texas Updated Data From AMEERA-1: Phase 1/2 Study of Amcenestrant (SAR439859), […]

The Use of Immunotherapy in Triple-Negative Breast Cancer

H&O Which patients with triple-negative breast cancer (TNBC) are eligible for immunotherapy? PS We generally use immunotherapy in TNBC for 2 indications. One indication is the […]

Highlights in Early and Metastatic Breast Cancer From the 2020 San Antonio Breast Cancer Symposium

A Review of Selected Presentations From the 2020 SABCS Virtual Symposium • December 8-11, 2020 Continued Efficacy of Neratinib in Patients With HER2-Positive Early-Stage Breast […]

Highlights in Metastatic Breast Cancer From the 2020 San Antonio Breast Cancer Symposium

A Review of Selected Presentations From the 2020 SABCS Virtual Symposium • December 8-11, 2020 Biomarker Evaluation in the Phase 3 ASCENT Study of Sacituzumab […]

Highlights in Metastatic Breast Cancer From the European Society for Medical Oncology Virtual Congress 2020

A Review of Selected Presentations From the ESMO Virtual Congress 2020 ASCENT: A Randomized Phase 3 Study of Sacituzumab Govitecan vs Treatment of Physician’s Choice in […]

Neratinib: An Option for HER2-Positive Metastatic Breast Cancer

Abstract: Metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer is currently incurable. The primary goals of treatment are to prolong survival while optimizing quality of […]

Neratinib in the Early-Stage/Extended Adjuvant Breast Cancer Patient

Abstract: Breast cancer is the most common tumor type observed in women in the United States. The majority of patients are diagnosed at an early stage, but […]

Highlights in Metastatic Breast Cancer From the 2019 San Antonio Breast Cancer Symposium

A Review of Selected Presentations From the 2019 SABCS • December 10-14, 2019 • San Antonio, Texas Tucatinib vs Placebo, Both Combined With Capecitabine and Trastuzumab, […]

Hem/Onc News

Abemaciclib Approved in HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer On September 28, the US Food and Drug Administration (FDA) approved abemaciclib (Verzenio, Lilly) as a […]

Highlights in Breast Cancer From the 2017 American Society of Clinical Oncology Annual Meeting

June 2-6, 2017 • Chicago, Illinois Subset of Patients With Heavily Pretreated Metastatic TNBC Respond to Pembrolizumab A subset of patients with heavily pretreated metastatic triple-negative […]

Antibody-Drug Conjugates in Breast Cancer

H&O What are antibody-drug conjugates (ADCs)? AB ADCs are drugs that contain an antibody linked to a chemotherapy agent. Accordingly, they have 3 components: an antibody […]

Is Precision Medicine Ready for Use in Breast Cancer?

H&O How do you define precision medicine? LP The term precision medicine is often used as shorthand for personalizing or tailoring treatment recommendations to the […]

Immunotherapy for the Treatment of Breast Cancer: Checkpoint Blockade, Cancer Vaccines, and Future Directions in Combination Immunotherapy

Abstract: Immunotherapy encompasses both vaccines that direct immune responses to tumor-associated antigens, and checkpoint blocking antibodies that inhibit immune system suppression by targeting key pathways mediated […]

Obesity and Breast Cancer: Risk, Outcomes, and Future Considerations

Abstract: The proportion of adults who are obese has increased dramatically in the United States over the last 30 years. Obesity has been linked to […]